StartUp Health’s Post

🎉 Exciting Milestone for Neurona Therapeutics! 🚀 #NeuronaTherapeutics #SeriesE #HealthcareInnovation In an impressive turnaround from last year's challenges, Neurona Therapeutics has successfully secured $120 million in Series E funding, marking a significant achievement for the company. 🌟💰 This funding round attracted a diverse group of investors, including Viking Global Investors, Cormorant Asset Management, LP Asset Management, The Column Group, LYFE Capital, Schroders Capital, Willett Advisors LLC, YSIOS CAPITAL PARTNERS S G E C R SA, EUCLIDEAN CAPITAL, LLC, SymBiosis, Pharos of Alexandria Ventures Investments, Berkeley Frontier Fund, Sphera Biotech Master Fund LP, Spur Capital Partners, UCB Ventures, and UC Investments, showcasing widespread confidence in Neurona's vision and potential. 🤝💼 Nearly a year after Neurona had to navigate a difficult funding environment, leading to staff reductions, the biotech firm has bounced back stronger. The company's resurgence is fueled by a positive early readout for its epilepsy cell therapy, NRTX-1001, which has shown promising results. 🚀🔬 This influx of capital will accelerate Neurona's phase 1/2 trial to a higher dose level in 2024, paving the way for further research into bilateral MTLE - a form of epilepsy affecting both sides of the brain. 🧠💉 This latest development is not just a testament to Neurona Therapeutics' resilience and dedication to innovation but also signals a hopeful future for epilepsy treatment. The company stands at the forefront of a transformative journey, aiming to make significant strides in healthcare and improve the lives of patients worldwide. 🌍❤️ #EpilepsyResearch #BiotechFunding #InnovationInHealthcare #FutureOfMedicine #PatientCare #ScienceMakingADifference

🚀 Exciting News for the Global Community! 🌐 Today, I'm thrilled to share a passion project that has been close to my heart and is now taking shape as the #First4Founders initiative. 🌟 At the core of this endeavor is my unwavering commitment to inspiring scientists, medical doctors, and biotech founders across the globe. I'm delighted to unveil a new milestone: the launch of our series, "Listen To The Biotech Expert," supported by great Strategic Advisors at CharaBio. 🎙 Episode 1 features Dr. Francesco Marincola, CSO at Sonata Therapeutics (a Flagship Pioneering company) With 30 years of experience in #oncology and #immunology across various modalities—from #smallmolecules to groundbreaking #celltherapy —Dr. Marincola's insights are a treasure trove for anyone passionate about advancing the frontiers of biotech. We will dive into the differences in R&D for a small molecule drug compared to cell therapies. His previous experience as CSO at Kite Pharma (Gilead’s Cell Therapy Division) adds an extra layer of depth to our conversation. And I look forward to learning more about Sonata’s Network Medicines™ that reprogram diseased cells to instead release curative signals, resulting in durable disease resolution 🔥 And the excitement doesn't end here! I'm thrilled to announce that our next virtual fireside chat will dive into the realm of #businessdevelopment in #Pharma. 🌐 #staytuned for tomorrow's big reveal as we unveil the next expert who will grace our platform. 🌍 To the #scientists , #medicaldoctors, and #biotechentrepreneurs: This initiative is for you. There is no limit to the what you can accomplish, the boundaries you can push in medicine, and the impact you can make. Let's come together, learn from each other, and continue driving the future of biotech. 🚀 Join us on this incredible journey! Have you got a question for Dr. Marincola? Feel free to email or DM me and we will select 3-5 questions from the registered attendees Francesco Marincola Link to the event here https://lnkd.in/dx3W9XHQ #First4Founders #biotechinnovation #ListenToTheExpert #CharaBio #BiotechLeaders #firesidechat

#investment I We're proud to share that we have joined a $157M Series B round in Engrail Therapeutics co-led by F-Prime Capital, Forbion and Norwest Venture Partners with participation from Red Tree Venture Capital, RiverVest Venture Partners, Longwood Fund, Eight Roads, Pivotal Life Sciences, and others. 🎯 Developing therapies for the treatment of #Neuropsychiatric and #Neurodevelopmental disorders including #anxiety disorders, #depression, #posttraumatic #stress disorder, and #rare #neurodegenerative diseases. 💼 Guillem Laporta, CFA 🔬 The lead-stage clinical compound ENX-102, is being evaluated in a multi-center phase 2 study for the treatment of generalized #anxiety disorder (#GAD) and has shown strong anxiolytic effects in the gold-standard preclinical model of GAD. 💥  Novel approaches that can provide sustained #anxiolytic efficacy while limiting the risk of addiction or dependence open the door to better care.💪 https://lnkd.in/du9vF9-N #vc #biotech ##innovation #impactinvesting  #ClinicalTrial #CNS Ver traducción

USD 17.4 million for precision medicine targeting neuropsychiatric and neurological disorders: TOP 100 Swiss startup STALICLA raises Series B. Congratulations and all the best onwards to the driven team of innovators Eric Painbeni, Laurent Forestier, Jean-Marc Hyvelin, Lynn-Allison Durham, Atul Mahableshwarkar, Laura Perez Cano, and Emre Guney! https://lnkd.in/eFPVTtQk Led by SPRIM Global Investments, with key participation from core investors, this funding includes a USD 3.8 million credit facility. About: STALICLA is a clinical stage biotech company advancing the first clinically validated precision medicine platform for patients with Neurodevelopmental Disorders (NDDs), with a first application in ASD. STALICLA has already identified and validated several subgroups of patients with ASD and corresponding treatment candidates. Stalicla was ranked among the TOP 100 Swiss Startups in 2022. #TOP100SSU #SwissStartups

As we grow older, our cells become less functional, accumulating errors that cause cell damage over time. As the errors accumulate, more and more of our cells become senescent, stopping proper function and increasing disarray in the surrounding cellular environment, ultimately contributing to the emergence and progress of age-associated diseases. Not for much longer. Rubedo Life Sciences, founded by Marco Quarta and Mark Gallop, is making it possible to treat these cells with newfound anti-aging therapeutics. Their platform identifies specific druggable targets and develops them into therapeutics that selectively target senescent pathologic cells, fighting the results of ageing. By addressing the cellular, fundamental cause of age-related diseases, Rubedo is a pioneer in the mission to preserve biological youth - and that’s why we joined their recent $40 million Series A round with Khosla Ventures, Ahren Innovation Capital, Hevolution Foundation, R42 Group, Modi Ventures, Shanda Group, Refactor Capital, IAG and others. https://lnkd.in/daVr8-UQ

Pretty proud of my long-time friend Thilo Kleinschmidt, MBA whom I've shared so many memories and even an apartment with: Thilo, Jens and their team at Kranus Health work on often neglected topics: Male Health and Urology Did you know that ... 1️⃣ In Germany alone, 6-8 million men suffer from erectile dysfunction? 2️⃣ Urology is covering both male (70%) and female patients (30%)? 3️⃣ Many diagnostics and therapies in Urology can be supported virtually via digital apps (e.g., against erectile dysfunction, prostate issues, incontinence)? Since 2021, the Kranus app has been listed in Germany as a DIGA, so it can be prescribed by doctors and reimbursement from health insurances is available ➡️ Check out Sifted's article for more details on this topic and their entrepreneurial journey

I am excited to share with you some impactful news from our client, Coya Therapeutics, Inc. In a remarkable achievement and milestone event on their mission to combat neurodegenerative diseases, especially ALS. 👏 CEO, Howard Berman, PhD brings a wealth of experience from a distinguished career in big pharma. His personal journey, driven by the challenges faced while caring for his father diagnosed with dementia, has fueled a passionate commitment to make a meaningful impact. BREAKING NEWS: 🌐 Coya Therapeutics recently announced a groundbreaking $26.5 million private placement, a testament to their dedication and potential breakthroughs in neurodegenerative treatments. This strategic move is poised to drive their innovative research and development forward. 🤝 Additionally, the collaboration with Dr. Reddy's Laboratories for the development and commercialization of COYA 302, an investigational combination therapy for ALS, is a significant leap forward. The $7.5 million upfront payment and potential future payments and royalties underscore the confidence in COYA 302's potential impact. 💡 COYA 302, stemming from a collaborative effort between Coya and Houston Methodist, is a beacon of hope in the realm of neurodegenerative diseases. The proprietary co-pack kit's focus on enhancing regulatory T cells offers promise for those battling ALS. 🚀 Howard's leadership, combined with the strategic partnerships and groundbreaking research at Coya, exemplifies their commitment to innovation and patient care. This mission-driven approach is not only inspiring but also indicative of the transformative impact they aim to achieve. 🌍 Kudos to Howard Berman, the entire Coya team, and their collaborators for their dedication to making a real difference in the lives of those affected by neurodegenerative conditions. This marks a special milestone for all of us, as we move closer to a future where ALS and similar diseases are no longer a formidable challenge. Congradulations to Arun Swaminathan, David Snyder, Daniel Barvin and the Coya team! #NeurodegenerativeDiseases #ALS #InnovationI #CoyaTherapeutics #MedicalBreakthroughs #MissionDrivenLeadership

Closing off the year with a deep appreciation for everyone who contributed to advancing #preclinicalresearch this year. We want to thank our dedicated staff, our innovative clients, and those who continue to advocate for better patient outcomes. Here's to another successful year of preclinical research in 2024! 🎆🎇🎆 #preclinicalCRO #oncologyresearch #neurologyresearch #preclinicalmodels #raredisease

One week left! Join us for an exciting day of life science innovation, networking and opportunity. ⏰ When: May 21, 2024, 9 AM - 3 PM. 📍 Where: Mansfield Bio-Incubator, 241 Francis Ave Mansfield, MA 02048 🌟 Featured: 13 handpicked #startups representing therapeutics (#oncology, #diabetes, #Parkinson's), #medicaldevices (#womenshealth, smudge-proof #glasses, #opioid detection), #diagnostics (cervical cancer) and #biotechnology (bio tools, genetic diseases, tissue engineering). In addition, there will be a graduation ceremony for the Spring 2024 #Mentoring Program cohort consisting of three presenting startups. 👥 Attending: Investors, entrepreneurs, mentors, life science professionals, business development experts, sponsors 🔍 Why attend: § Learn about innovations that will revolutionize healthcare § Explore investment opportunities § Network with industry veterans and the new generation shaping the future of life sciences § Showcase your products and services to a targeted audience of professionals and stakeholders The Prizes Are: $20,000 for first place; $12,000 for second place; $8,000 for third place. We look forward to seeing you in Mansfield. Please feel free to share this information with your colleagues. https://lnkd.in/eGyFAxXG